<code id='881F0F6437'></code><style id='881F0F6437'></style>
    • <acronym id='881F0F6437'></acronym>
      <center id='881F0F6437'><center id='881F0F6437'><tfoot id='881F0F6437'></tfoot></center><abbr id='881F0F6437'><dir id='881F0F6437'><tfoot id='881F0F6437'></tfoot><noframes id='881F0F6437'>

    • <optgroup id='881F0F6437'><strike id='881F0F6437'><sup id='881F0F6437'></sup></strike><code id='881F0F6437'></code></optgroup>
        1. <b id='881F0F6437'><label id='881F0F6437'><select id='881F0F6437'><dt id='881F0F6437'><span id='881F0F6437'></span></dt></select></label></b><u id='881F0F6437'></u>
          <i id='881F0F6437'><strike id='881F0F6437'><tt id='881F0F6437'><pre id='881F0F6437'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:32
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          How housing is health care on Long Island
          How housing is health care on Long Island

          LongIslandisinthemidstofahousingcrisis.Justlikeinmanyotherpartsofthecountry,LongIslandersarehavingat

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

          LongtimeBluebirdBioCEONickLeschlyWendyMaeda/TheBostonGlobeSometwoyearsaftersplittingbiotechcompanyBl